Quick Links
Past Events

Credit Designation

Physicians' Education Resource®, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Pfizer Inc.

Privacy Policy
Terms & Conditions
Executive Board
Faculty Portal
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 1-609-378-3701

Copyright © 2018
Physicians’ Education Resource ®, LLC.
All rights reserved.

ASCO GU: Emerging Paradigm Shifts in Renal Cell Carcinoma: A Critical Assessment of Adjuvant Treatment Data

ASCO GU: Emerging Paradigm Shifts in Renal Cell Carcinoma: A Critical Assessment of Adjuvant Treatment Data

An Ancillary Satellite Symposium held adjunct to the 2018 Genitourinary Cancers Symposium

Date: Thursday February 8, 2018

Time: 7:00 PM – 9:00 PM
Dinner and registration: 6:30 PM – 7:00 PM

Location: Marriott Marquis,
780 Mission St.
San Francisco, CA 94103
Room: Golden Gate A

Program Overview

Renal cell carcinoma (RCC) remains one of most difficult to treat of the solid tumors. However, RCC treatment is also one of the most rapidly evolving fields in oncology. New data suggest impending changes in both early-stage and metastatic RCC, including novel indications, combination approaches, and optimized adjuvant strategies. However, the use of adjuvant therapy for RCC remains an area of controversy. This activity will bring together renowned experts in RCC for in-depth critical review and debate on evidence from studies of adjuvant RCC therapy. To help clinicians synthesize available information, this satellite symposium will include didactic overviews of current data on adjuvant therapy, risk assessment, and patient selection; case reviews; and faculty debates on key areas of controversy and clinical uncertainty around the use of adjuvant therapy for RCC. The format of this activity will enable the audience to interact with the expert faculty panel and to gain evidence-based perspective on the use of adjuvant therapy for RCC.

Acknowledgement of Commercial Support

This activity is supported by educational an grant from Pfizer Inc.

Target Audience:

This educational program is directed toward urologists, medical oncologists, surgical oncologists, and radiation oncologists interested in the treatment of RCC. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with RCC will be invited to participate.

Learning Objectives

Upon completion of this activity, participants should be better prepared to:

  • Substantiate treatment decisions in the management of RCC at key decision points along the disease continuum based on the most pertinent clinical trial evidence for targeted therapy
  • Integrate knowledge of patient selection, single-agent, and combination strategies in the context of mechanisms of action, kinetics of response, best practices in monitoring, and key information that informs adjuvant treatment in the care of patients with RCC
  • Manage treatment-related toxicities as a component of therapeutic decision making in adjuvant treatment settings for patients with RCC
  • Evaluate recent clinical trial data, key ongoing trials, and how emerging adjuvant strategies may further impact the RCC treatment landscape

Program Chair

Robert A. Figlin, MD, FACP
Steven Spielberg Family Chair in Hematology Oncology
Professor of Medicine and Biomedical Sciences
Director, Division of Hematology/Oncology
Deputy Director, Integrated Oncology Service Line
Deputy Director, Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, CA

Become a Member

Forgot Password?
Calendar of Events
Filter By